Octant emerges with $30M to untangle, exploit pathways hit by dirty drugs

Study will evaluate the safety, tolerability and pharmacokinetics (PK) of OCT-980 in healthy volunteers

Initiation of the study marks Octant’s transition to a clinical-stage company